Applicant, as named in the Orange Book
Almirall
Next listed expiry: Seysara on 9 Feb 2033. 3 products with live protection, 3 without.
Products with listed protection
| Drug | Ingredient | Earliest generic entry | Basis |
|---|
| Seysara NDA 209521 · 3 strengths sarecycline hydrochloride | sarecycline hydrochloride | 9 Feb 2033 patent | patent |
| Aczone NDA 207154 dapsone | dapsone | 18 Nov 2033 patent | patent |
| Klisyri NDA 213189 tirbanibulin | tirbanibulin | 7 Sep 2038 patent | patent |
Recent events
- Aczone · Generic approved · ANDA 213414, AlembicApproved 25 Jun 2026·Detected 25 Oct 2026
- Altabax · Enters 12-month window basis: patentListed date 14 Feb 2027·Detected 24 Oct 2026
Products without listed protection (3)
| Drug | Ingredient | Earliest generic entry | Basis |
|---|
| Aczone NDA 021794 dapsone | dapsone | open now no listed protection | no listed protection |
| Azelex NDA 020428 azelaic acid | azelaic acid | open now no listed protection | no listed protection |
| Cordran NDA 016455 flurandrenolide | flurandrenolide | open now no listed protection | no listed protection |